Hemab Therapeutics Holdings, Inc. COAG
43.10 USD +1.92 (+4.66%)
At closeNov 3, 2026, 4:32 PM EST
43.10 0.00 0.00%
After hours · Nov 3, 4:32 PM ET
41.15 Day range 44.36
23.00 52-week range 55.42
- YTD
- +26.76%
- 1 year
- +26.76%
- Market cap
- 2.01B
- EPS (ttm)
- -4.33
- Shares out
- 46.71M
- Forward P/E
- -16.92
- YTD return
- +26.76%
- 1-year return
- +26.76%
- Volume
- 465.77K
- Avg volume
- 453.56K
- Open
- 41.90
- Previous close
- 41.18
- Day's range
- 41.15 – 44.36
- 52-week range
- 23.00 – 55.42
- Price target
- 62.67 (+45.4%)
- Earnings date
- Nov 16, 2026
2Y +9.10 (+26.76%)
Key statistics
- Enterprise value
- 1.47B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 457.46M
- Total debt
- 1.03M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 37.74
- 200-day average
- 36.82
Analyst view
Price target (mean) 62.67 +45.4% upside
Now 43.10
- Target (low)
- 58.00
- Target (mean)
- 62.67
- Target (high)
- 70.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 16, 2026
Expected Nov 16, 2026. Consensus EPS estimate -0.51529.
Financials — quick view
COAG Revenue — quarterly 0
COAG Net income — quarterly -24.15M
COAG EPS — quarterly -0.80
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 16, 2026 | Sep 30, 2026 | -0.49608 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.7325 | -0.80 | -0.07 | -9.22% |
| May 21, 2026 | Mar 31, 2026 | -23.25 | -23.98 | -0.73 | -3.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | JP Morgan | init | — | Overweight |
| Oct 12, 2026 | Rodman & Renshaw | init | — | Buy |
| Aug 12, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 13, 2026 | Jefferies | main | Buy | Buy |
| Jul 13, 2026 | Wedbush | main | Outperform | Outperform |
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hemab.com
News
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026 
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 - Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56
Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened 
Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy? 
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts 
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert 
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding 
Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket 
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64
Your note
Sign in to keep a note on COAG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MARAGANORE JOHN M | Director | Conversion of Exercise of derivative security | May 3, 2026 | 35,948 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 3, 2026 | 4,180,550 |
| RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 11, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 15, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 16.72% | 7,808,627 | 336.55M | Jun 29, 2026 |
| Novo Holdings A/S | 8.95% | 4,180,550 | 180.18M | Jun 29, 2026 |
| FMR, LLC | 7.92% | 3,697,837 | 159.38M | Jun 29, 2026 |
| Capital International Investors | 7.72% | 3,603,876 | 155.33M | Jun 29, 2026 |
| Deep Track Capital, Lp | 7.71% | 3,602,093 | 155.25M | Jun 29, 2026 |
| Siren, L.L.C. | 4.47% | 2,086,834 | 89.94M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.51% | 3,506,543 | 151.13M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.19% | 555,543 | 23.94M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 1.14% | 531,382 | 22.90M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.12% | 523,853 | 22.58M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.10% | 514,858 | 22.19M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.08% | 506,791 | 21.84M | Sep 29, 2026 |